J Korean Med Sci.  2010 Apr;25(4):583-588. 10.3346/jkms.2010.25.4.583.

Rebamipide May Be Comparable to H2 Receptor Antagonist in Healing Iatrogenic Gastric Ulcers Created by Endoscopic Mucosal Resection: A Prospective Randomized Pilot Study

• Kim YJ
• Cheon JH
• Lee SK
• Kim JH
• Lee YC

• KMID: 1792929
• DOI: http://doi.org/10.3346/jkms.2010.25.4.583

Abstract

Endoscopic mucosal resection (EMR) results in the formation of iatrogenic gastric ulcers and the optimal treatments for such ulcers are still unclear. We aimed to evaluate the efficacy of rebamipide in the management of EMR-induced ulcers by comparing it with an H2 receptor antagonist. After EMR, patients were randomly assigned into either rebamipide or famotidine groups. All patients received a one-week lansoprazole 30 mg q.d. therapy followed by three-week famotidine (20 mg b.i.d.) or rebamipide (100 mg t.i.d.) therapy. Four weeks after the treatments, ulcer sizes, stages, bleeding rates, and ulcer-related symptoms were compared using endoscopy and a questionnaire. A total of 63 patients were enrolled in this study. Finally, 51 patients were analyzed, 26 in rebamipide and 25 in famotidine group. Baseline characteristics were not significantly different between the two groups. Four weeks after EMR, the two groups were comparable in terms of ulcer reduction ratio (P=0.297), and ulcer stage (P=1.000). Moreover, no difference was observed with regard to ulcer-related symptoms, drug compliance, adverse drug event rates, and bleeding rates. Our data suggest that rebamipide is not inferior to famotidine in healing iatrogenic gastric ulcers, and could be a therapeutic option in the treatment of such ulcers.

Keyword

Rebamipide; Stomach Ulcer, Endoscopic Mucosal Resection; H2 Receptor Antagonist

MeSH Terms

Adult
Aged
Aged, 80 and over
Alanine/*analogs & derivatives/therapeutic use
Anti-Ulcer Agents/*therapeutic use
Endoscopy, Gastrointestinal/*adverse effects
Famotidine/*therapeutic use
Histamine H2 Antagonists/*therapeutic use
Humans
Iatrogenic Disease
Male
Middle Aged
Pilot Projects
Prospective Studies
Quinolones/*therapeutic use
Receptors, Histamine H2/metabolism
Stomach Ulcer/*drug therapy/*etiology/pathology
Wound Healing
Anti-Ulcer Agents
Histamine H2 Antagonists
Quinolones
Receptors, Histamine H2
Alanine
Famotidine

Figure

• 

  Fig. 1 Flow diagram of the study. EMR, endoscopic mucosal resection; PPI, proton pump inhibitor; iv, intravenous.

• 

  Fig. 2 Flow diagram of patient enrollment, assignment, and completion of the study. APC, argon plasma coagulation.

Reference

1. Conio M, Ponchon T, Blanchi S, Filiberti R. Endoscopic mucosal resection. Am J Gastroenterol. 2006. 101:653–663.

2. Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, Hosokawa K, Shimoda T, Yoshida S. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001. 48:225–229.

3. Lee JH, Kim JJ. Endoscopic mucosal resection of early gastric cancer: Experiences in Korea. World J Gastroenterol. 2007. 13:3657–3661.

4. Tanaka M, Ono H, Hasuike N, Takizawa K. Endoscopic submucosal dissection of early gastric cancer. Digestion. 2008. 77:Suppl 1. 23–28.

5. Wallace JL. Recent advances in gastric ulcer therapeutics. Curr Opin Pharmacol. 2005. 5:573–577.

6. Szabo S, Vincze A, Sandor Z, Jadus M, Gombos Z, Pedram A, Levin E, Hagar J, Iaquinto G. Vascular approach to gastroduodenal ulceration: new studies with endothelins and VEGF. Dig Dis Sci. 1998. 43:9 Suppl. 40S–45S.

7. Esaki M, Aoyagi K, Matsumoto T, Kuwano Y, Shimizu M, Fujishima M. Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. Eur J Gastroenterol Hepatol. 2002. 14:365–369.

8. Piazuelo E, Lanas A, Jimenez P, García-Gonzalez A, Esteva F. In vitro wound repair by human gastric fibroblasts: implications for ulcer healing. Dig Dis Sci. 1998. 43:1230–1240.

9. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998. 43:9 Suppl. 5S–13S.

10. Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004. 49:202–209.

11. Sakita T, Fukutomi H. Yoshitoshi Y, editor. Endoscopic diagnosis. Ulcer of the stomach and duodenum. 1971. Tokyo: Nankodo;198–208.

12. Ye BD, Cheon JH, Choi KD, Kim SG, Kim JS, Jung HC, Song IS. Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial. Aliment Pharmacol Ther. 2006. 24:837–843.

13. Lee SY, Kim JJ, Lee JH, Kim YH, Rhee PL, Paik SW, Rhee JC. Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. Gastrointest Endosc. 2004. 60:213–217.

14. Bate CM, Wilkinson SP, Bradby GV, Bateson MC, Hislop WS, Crowe JP, Willoughby CP, Peers EM, Richardson PD. Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer. Gut. 1989. 30:1323–1328.

15. Walan A, Bader JP, Classen M, Lamers CB, Piper DW, Rutgersson K, Eriksson S. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989. 320:69–75.

16. Schepp W, Classen M. Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. Scand J Gastroenterol. 1995. 30:511–514.

17. Lauritsen K, Rune SJ, Wulff HR, Olsen JH, Laursen LS, Havelund T, Astrup L, Bendtsen F, Linde J, Bytzer P. Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial. Gut. 1988. 29:249–253.

18. Lauritsen K, Rune SJ, Bytzer P, Kelbaek H, Jensen KG, Rask-Madsen J, Bendtsen F, Linde J, Højlund M, Andersen HH. Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med. 1985. 312:958–961.

19. Yamaguchi Y, Katsumi N, Tauchi M, Toki M, Nakamura K, Aoki K, Morita Y, Miura M, Morozumi K, Ishida H, Takahashi S. A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration. Aliment Pharmacol Ther. 2005. 21:Suppl 2. S111–S115.

20. Kojima T, Parra-Blanco A, Takahashi H, Fujita R. Outcome of endoscopic mucosal resection for early gastric cancer: review of the Japanese literature. Gastrointest Endosc. 1998. 48:550–554.

21. Jang JS, Lee EJ, Lee SW, Lee JH, Roh MH, Han SY, Choi SR, Jeong JS. Endoscopic submucosal dissection for early gastric cancer and gastric adenoma. Korean J Gastroenterol. 2007. 49:356–363.

22. Maity P, Biswas K, Roy S, Banerjee RK, Bandyopadhyay U. Smoking and the pathogenesis of gastroduodenal ulcer--recent mechanistic update. Mol Cell Biochem. 2003. 253:329–338.